Arcus Biosciences Gross Margin 2017-2022 | RCUS

Current and historical gross margin for Arcus Biosciences (RCUS) over the last 10 years. The current gross profit margin for Arcus Biosciences as of March 31, 2022 is %.
Arcus Biosciences Gross Margin Historical Data
Date TTM Revenue TTM Gross Profit Gross Margin
2022-03-31 $0.39B $0.39B 100.00%
2021-12-31 $0.38B $0.38B 100.00%
2021-09-30 $0.04B $0.04B 100.00%
2021-06-30 $0.09B $0.09B 100.00%
2021-03-31 $0.09B $0.09B 100.00%
2020-12-31 $0.08B $0.08B 100.00%
2020-09-30 $0.08B $0.08B 100.00%
2020-06-30 $0.02B $0.02B 100.00%
2020-03-31 $0.02B $0.02B 100.00%
2019-12-31 $0.02B $0.02B 100.00%
2019-09-30 $0.01B $0.01B 100.00%
2019-06-30 $0.01B $0.01B 100.00%
2019-03-31 $0.01B $0.01B 100.00%
2018-12-31 $0.01B $0.01B 100.00%
2018-09-30 $0.01B $0.01B 100.00%
2018-06-30 $0.00B $0.00B 100.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.353B $0.383B
Arcus Biosciences is a biopharmaceutical company. It focused on creating innovative cancer immunotherapies. The company's product portfolio includes AB928, AB122, AB154 and AB680. AB928 which is in its final phase is a potent and selective dual antagonist of the adenosine receptors. AB122 which is in its Phase1 is a monoclonal antibody which potently and selectively blocks a protein called PD-1. AB154 is a monoclonal antibody which potently and selectively blocks a novel immune checkpoint called TIGIT. AB680, which is in its Phase1 is a potent and selective inhibitor of CD73, the enzyme responsible for the extracellular production of adenosine within the tumor micro-environment. Arcus Biosciences is based in Hayward, CA.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.981B 9.98
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
Biohaven Pharmaceutical Holding (BHVN) United States $9.996B 0.00
QIAGEN (QGEN) Netherlands $9.982B 15.76
Ginkgo Bioworks Holdings (DNA) United States $4.276B 0.00
Emergent Biosolutions (EBS) United States $1.424B 6.09
Myovant Sciences (MYOV) United Kingdom $0.930B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.444B 0.00
Gelesis Holdings (GLS) United States $0.355B 0.00
Zymeworks (ZYME) Canada $0.299B 0.00
Ambrx Biopharma (AMAM) United States $0.138B 0.00
Enzo Biochem (ENZ) United States $0.118B 24.20
SQZ Biotechnologies (SQZ) United States $0.090B 0.00